Evommune

United States · Research

Evommune is a clinical-stage biotechnology company dedicated to discovering and developing innovative therapies for immune-mediated chronic inflammatory diseases. The company aims to address the root causes of these conditions, which are responsible for a significant number of global deaths. By focusing on the underlying mechanisms of inflammation, Evommune seeks to provide effective solutions rather than just managing symptoms. The company utilizes a structure-based drug discovery engine and computational chemistry to create highly selective molecules that target inflammation. Evommune's research and development efforts emphasize safety, efficacy, and regulatory expertise, with a commitment to advancing therapies for underserved patient populations. They are building a broad portfolio of clinical-stage candidates designed to halt disease progression and offer superior therapeutic potential compared to existing treatments. Evommune fosters a collaborative and diverse work environment, promoting professional growth and a shared commitment to scientific breakthroughs in immunology. Recently, the company secured $115 million in Series C financing to further accelerate its clinical-stage pipeline, reflecting strong investor confidence in its mission and approach.